EP0110372A1 - 1-Phenylisoquinoline derivatives, process for their preparation, pharmaceutical compositions containing these compounds and their use - Google Patents
1-Phenylisoquinoline derivatives, process for their preparation, pharmaceutical compositions containing these compounds and their use Download PDFInfo
- Publication number
- EP0110372A1 EP0110372A1 EP83111922A EP83111922A EP0110372A1 EP 0110372 A1 EP0110372 A1 EP 0110372A1 EP 83111922 A EP83111922 A EP 83111922A EP 83111922 A EP83111922 A EP 83111922A EP 0110372 A1 EP0110372 A1 EP 0110372A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- general formula
- compound
- hydrogen
- radicals
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- substituted 3-hydroxymethylisoquinolines have spasmolytic properties.
- DE-OS 31 50 876 3,4-dihydroisoquinolines substituted in the 3-position with an alkylene amino group are known which have analgesic and antidepressant activity.
- Isoquinolines with pyridyl substituents in the 3-position are active against Mycoplasma gallisepticum.
- Dihydropyridines as substituents in the 3-position of isoquinoline are described in DE-OS 22 10 667 as coronary dilators.
- the present invention relates to novel 1-phenylisoquinoline derivatives substituted in the 3-position with a basic ring and having psychotropic effects. their preparation, pharmaceutical preparations containing these compounds and their use.
- the compounds II are either converted in one step up to fully aromatic isoquinoline derivatives III, or the ring is closed first to give the 3,4-dihydro compound IV, wherein m, n, R 2 and R 3 have the meaning given for formula I and Py is the 3- or 4-pyridyl radical, and this is then dehydrated to the isoquinoline derivative III, analogously to the information from A. Pictet and FW Kay in Ber . 42, 1973-1989 (1909) or E. boss, F. Berger and W. Kuntara, Ber. 63, 134-141 (1930).
- the compounds III are then mixed with the alkylating agent Z- R 4 alkylated.
- the quaternary pyridinium salts formed in this way are advantageously reduced with lithium aluminum hydride, sodium cyanoborohydride or sodium borohydride in a solvent such as ether, tetrahydrofuran, ethanol, water or in a mixture of these solvents, at temperatures between 0 ° and 100 ° C. It is also advantageous to add bases such as sodium hydroxide, as described in the literature (Synthesis 1979, 281; J. Am. Chem. Soc. 102, 1064 (1980); Ann. 1978, 1963).
- the compounds of general formula III are catalytically hydrogenated, for example with palladium on animal charcoal or with platinum oxide as a catalyst in ethanolic hydrochloric acid at room temperature and normal pressure, until the theoretical amount of hydrogen has been taken up.
- varying amounts of the tetrahydroisoquinoline compound VII are formed, in which n, m, R 2 , R 3 , A and B have the meaning given for the formula I and where the group NR 4 is NH, which can be separated off by column chromatography, for example on silica gel with chloroform / methanol.
- the starting materials of the general formula II are prepared as follows from 3-cyanopyridine with 3-pyridylbenzyl ketone with benzylmagnesium chloride (cf. J. Am. Chem. Soc. 78, 674-676 (1956)).
- ketones can be obtained by the condensation described in J. Med. Chem. 12, (1969), 851-854 of ethyl phenylacetate or of benzyl cyanides with ethyl nicotinate or ethyl isotonicate.
- ketones thus obtained react with hydroxylamine to give the oximes, which are catalytically reduced to give the amines.
- the reaction with the corresponding acid chlorides gives the amides of the formula II.
- the compounds of general formula I according to the invention show effects on the central nervous system. They especially cancel the ptosis caused by tetrabenazine in mice. Furthermore, these compounds inhibit the reuptake of noradrenaline in synaptosomes. On the basis of these properties, the compounds according to the invention can be used as active ingredients in antidepressant drugs.
- mice Male mice (Gassner, NMRI) with a body weight of 20-30 g were used as test animals. 6 animals were tested in a group. The compounds were suspended in 1% methyl-hydroxy-ethyl-cellulose (MH) and administered to the animals intraperitoneally (i.p.) in a volume of 10 ml / kg body weight. The compounds according to the invention were administered in doses of 3, 10, 30 and 100 mg / kg i.p. given.
- MH methyl-hydroxy-ethyl-cellulose
- ALD 50 The acute lethal dose was determined graphically from the number of animals that died within 24 hours after application of the compound. It is in the. listed in Table 1 below.
- mice Male mice (Gassner, NMRI) with a body weight of 20-25 g were used as test animals. 5 each Animals were tested in a group. The compounds were suspended in 1% methyl-hydroxy-ethyl-cellulose and administered to the animals intraperitoneally (i.p.) in a volume of 10 ml / kg body weight. The compounds according to the invention were administered in doses of 5, 10 and 20 mg / kg i.p. tested. The control group received only 10 ml / kg MH i.p. without active ingredient.
- the compounds were administered to the animals i.p. 30 minutes prior to tetrabenazine (TBZ) administration. administered.
- the control group received only 1% MH and TBZ on the same schedule as the animals treated with the test substances.
- the ED 50 defines the dose that reduces the average ptosis index (maximum 4) by 50%.
- IC 50 (inhibition concentration) values in Table 1 below indicate the concentration of the test substances which inhibit the absorption of 14 C-noradrenaline by 50%.
- the compounds of the general formula I according to the invention and their salts with pharmacologically acceptable acids are active as antidepressants within a wide dosage range.
- the amount of the administered dose is of course dependent on the type of treatment desired, from the A nassembletagen and from the state, the type and the size of the mammal to be treated.
- the daily dose varies between 10 - 400 mg of active substance p ro human, preferably zwishcen 20-200 mg, with single doses from 10 to 100 mg, preferably one to three times a day.
- the dose is 2 - 150 mg, preferably 5-100 mg daily.
- the compounds can be used alone or mixed with conventional pharmaceutical auxiliary substances and / or carriers.
- the compounds are brought into suitable dosage forms by conventional methods, such as tablets, push-fit capsules, aqueous, alcoholic or oily solutions.
- inert carriers e.g. Magnesium carbonate, milk sugar or corn starch can be used.
- Vegetable oils such as olive oil or sunflower oil are particularly suitable as oily carriers or solvents.
- the starting material is shown as follows.
- This cyanoketone (31.0 g) is hydrolyzed in 6N hydrochloric acid at 80-90 ° C.
- the hydrochloride of 3,4-Dimethoxy-3-pyridylketcn crystallized from ethanol with mp 188 -. 191 0 C and the free base shows a melting point of 60 -. 64 ° C.
- the compound is converted to the oxime without further purification.
- the starting material is shown as follows.
- the aqueous phase is separated off and made strongly alkaline with potassium hydroxide.
- the product is extracted with toluene and, after the toluene has been distilled off, chromatographed on silica gel with chloroform-ethyl acetate (8: 2). 25 g of an oily base are isolated which, using ethanolic hydrochloric acid, assigns a hydrochloride with a melting point of 255-259 ° C.
- the benzyl magnesium chloride compound in ether is prepared from 6.6 g of magnesium shavings and 34.2 g of benzyl chloride by known methods. While cooling with ice, 26 g of 4-cyanopyridine in 200 ml of ether are added dropwise to the Grignard compound, a thick crystal slurry being formed which is stirred at room temperature for 20 hours.
- reaction mixture is slowly hydrolyzed with 50 ml of water and 100 ml of 5N hydrochloric acid.
- the aqueous phase was heated for 1.5 hours on a steam bath, made alkaline with potassium carbonate and extracted with toluene. After crystallization from ether, 5.6 g of the ketone with a melting point of 94-96 ° is isolated from the toluene phase.
- the mother liquor contains 5.6 g of a mixture of substances, which is separated by chromatography. 2.8 g of 1-phenyl-3- (piperidin-4-yl) isoquinoline are isolated, which melts at 238-242 ° C. as the hydrochloride.
- the base is released from 1.3 g of 1- (2-methylphenyl) -3- (piperidin-4-yl) isoquinoline hydrochloride with potassium carbonate and dissolved in 40 ml of toluene. This solution is stirred with 0.82 g sodium carbonate, 0.1 g potassium iodide and 0.61 g allyl bromide for 15 hours at room temperature and then for a further 2 hours at 50 ° C. The reaction mixture is partitioned between toluene and water and 1.2 g of a light oil are isolated from the toluene solution, which can be converted into 1.4 g of the oxalate with melting point 217-219 ° C. in isopropanol with oxalic acid.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Substituierte 3-Hydroxymethylisochinoline haben nach DE-OS 22 46 307 spasmolytische Eigenschaften. Nach DE-OS 31 50 876 sind in 3-Stellung mit einer Alkylenaminogruppe substituierte 3,4-Dihydroisochinoline bekannt, die analgetische und antidepressive Wirkung besitzen. Isochinoline mit Pyridylsubstituenten in 3-Stellung (vgl. Eur. J. Med. Chem. 10, 603 (1975)) sind gegen Mycoplasma gallisepticum aktiv. Dihydropyridine als Substituenten in 3-Stellung von Isochinolin werden in DE-OS 22 10 667 als Coronardilatatoren beschrieben.According to DE-OS 22 46 307, substituted 3-hydroxymethylisoquinolines have spasmolytic properties. According to DE-OS 31 50 876, 3,4-dihydroisoquinolines substituted in the 3-position with an alkylene amino group are known which have analgesic and antidepressant activity. Isoquinolines with pyridyl substituents in the 3-position (cf. Eur. J. Med. Chem. 10, 603 (1975)) are active against Mycoplasma gallisepticum. Dihydropyridines as substituents in the 3-position of isoquinoline are described in DE-OS 22 10 667 as coronary dilators.
Die vorliegende Erfindung betrifft neue in 3-Stellung mit einem basischen Ring substituierte 1-Phenylisochinolinderivate mit psychotropen Wirkungen, Verfahren zu. ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Präparate und deren Anwendung.The present invention relates to novel 1-phenylisoquinoline derivatives substituted in the 3-position with a basic ring and having psychotropic effects. their preparation, pharmaceutical preparations containing these compounds and their use.
Gegenstand der Erfindung sind 1-Phenylisochinolinderivate der allgemeinen Formel I
- R1 Wasserstoff oder zusammen eine Bindung bedeuten, und
- R2 Wasserstoff, Halogen, Hydroxy, Nitro, Amino, C1-C6-Alkyl- oder C1-C6-Alkoxyreste bedeutet, und
- R3 Wasserstoff, Halogen, Hydroxy, Nitro, Amino, C1-C6-Alkyl- oder C1-C6-Alkoxyreste, Benzyloxy, Methylendioxy oder Äthylendioxygruppe bedeutet.
- R 1 is hydrogen or together a bond, and
- R 2 denotes hydrogen, halogen, hydroxy, nitro, amino, C 1 -C 6 alkyl or C 1 -C 6 alkoxy radicals, and
- R 3 is hydrogen, halogen, hydroxy, nitro, amino, C 1 -C 6 alkyl or C 1 -C 6 alkoxy, benzyloxy, methylenedioxy or ethylenedioxy group.
Bevorzugt sind solche Verbindungen der allgemeinen Formel I, in denen m und n unabhängig voneinander eins oder zwei,
- 4 4 A und B eine CH2- oder N-R -Gruppe, wobei R4, Wasserstoff oder ein geradkettiger oder verzweigter, gesättigter oder ungesättigter C1-C6-Alkylrest ist, bedeuten, und die Reste
- R 1 Wasserstoff oder zusammen eine Bindung bedeuten, und
- R2 Wasserstoff, Halogen, Hydroxy, Nitro, Amino, einen C1-C4-Alkyl- oder C1-C4-Alkoxyreste und
- R Wasserstoff, Halogen, Hydroxy, Nitro, Amino, einen C1-C4-Alkyl- oder C1-C4-Alkoxyreste bedeuten.
- Von besonderem Interesse sind Verbindungen der Formel I, in der m und n eins oder zwei,
- A und B eine CH2- oder N-R4 -Gruppe, wobei R4 Wasserstoff oder einen geradkettigen oder verzweigten C1-C4-Alkylrest, insbesondere der Methyl, Ethyl, Propyl, iso-Propyl, Butyl oder iso-Butylrest ist, die Reste
- R Wasserstoff oder zusammen eine Bindung bedeuten,
- R2 Wasserstoff, Fluor, Chlor, Brom, Hydroxy, Amino, Methyl, Ethyl, Methoxy oder Ethoxy, bevorzugt in ortho und/oder para-Position bedeutet und
- R3 Wasserstoff, Fluor, Chlor, Brom, Hydroxy, Amino, Methyl, Ethyl, Methoxy oder Ethoxy, bevorzugt in 6- und/oder 7-Position,bedeutet.
- Von ganz besonderem Interesse sind Verbindungen der Formel I, in der m und n eins,
- A und B eine CH2- oder N-R4-Gruppe, wobei R4, Wasserstoff, Methyl, Ethyl oder Propyl ist, die Reste
- R zusammen eine Bindung bedeuten,
- R Wasserstoff, Fluor, Chlor, Hydroxy, Methyl oder Methoxy bevorzugt in ortho-Position bedeutet und
- R 3 Wasserstoff, Fluor, Chlor, Hydroxy, Methyl oder Methoxy bevorzugt in 6 und/oder 7-Position bedeutet.
- 4 4 A and B are a CH2 or NR group, where R 4 is hydrogen or a straight-chain or branched, saturated or unsaturated C 1 -C 6 -alkyl radical, and the radicals
- R 1 is hydrogen or together a bond, and
- R 2 is hydrogen, halogen, hydroxy, nitro, amino, a C 1 -C 4 alkyl or C 1 -C 4 alkoxy radicals and
- R is hydrogen, halogen, hydroxyl, nitro, amino, a C 1 -C 4 alkyl or C 1 -C 4 alkoxy radicals.
- Of particular interest are compounds of the formula I in which m and n are one or two,
- A and B are a CH 2 or NR 4 group, wherein R 4 is hydrogen or a straight-chain or branched C 1 -C 4 alkyl radical, in particular the methyl, ethyl, propyl, iso-propyl, butyl or iso-butyl radical, which Leftovers
- R is hydrogen or together a bond,
- R 2 is hydrogen, fluorine, chlorine, bromine, hydroxyl, amino, methyl, ethyl, methoxy or ethoxy, preferably in the ortho and / or para position and
- R 3 is hydrogen, fluorine, chlorine, bromine, hydroxy, amino, methyl, ethyl, methoxy or ethoxy, preferably in the 6- and / or 7-position.
- Of particular interest are compounds of the formula I in which m and n are one,
- A and B represent a CH 2 or NR 4 group, where R 4 is hydrogen, methyl, ethyl or propyl, the residues
- R together represent a bond
- R is hydrogen, fluorine, chlorine, hydroxyl, methyl or methoxy, preferably in the ortho position and
- R 3 is hydrogen, fluorine, chlorine, hydroxyl, methyl or methoxy, preferably in the 6 and / or 7 position.
Das Verfahren zur Herstellung der Verbindungen der allgemeinen Formel I ist dadurch gekennzeichnet, daß man
- a) eine Verbindung der allgemeinen Formel II
- b) eine Verbindung der allgemeinen Formel III katalytisch reduziert zu einer Verbindung der allgemeinen Formel I, worin m, n, R 2, R 3, A und B die zur Formel I genannten Bedeutungen haben und die Reste R1 und R4 gleich Wasserstoff sind, und gegebenenfalls eine so erhaltene Verbindung der allgemeinen Formel I mit einem Alkylierungsmittel der allgemeinen Formel Z-R4 umsetzt zu einer Verbindung der allgemeinen Formel I, worin m, n, R 2, R 3, A und B die zur Formel I genannten Bedeutungen haben und die Reste R1 Wasserstoff und R 4 Benzyl oder einen geradkettigen oder verzweigten, gesättigten oder ungesättigten C1-C6-Alkylrest bedeuten.
- a) a compound of general formula II
- b) a compound of the general formula III catalytically reduced to a compound of the general formula I, in which m, n, R 2 , R 3 , A and B have the meanings given for the formula I and the radicals R 1 and R 4 are hydrogen , and optionally a compound of the general formula I thus obtained is reacted with an alkylating agent of the general formula ZR 4 to give a compound of the general formula I in which m, n , R 2 , R 3 , A and B have the meanings given for the formula I and the radicals R 1 are hydrogen and R 4 is benzyl or a straight-chain or branched, saturated or unsaturated C 1 -C 6 -alkyl radical.
Bei der Verfahrensweise a) werden die Verbindungen II entweder in einem Schritt bis zu vollaromatischen Isochinolinderivaten III umgesetzt, oder der Ringschluß erfolgt zuerst zur 3,4-Dihydroverbindung IV,
Die Verbindungen III werden dann mit dem Alkylierungsmittel Z-R 4 alkyliert. Die Reduktion der so entstehenden quartären Pyridiniumsalze wird vorteilhaft mit Lithiumaluminiumhydrid, Natriumcyanoborhydrid oder Natriumborhydrid in einem Lösungsmittel wie Ether, Tetrahydrofuran, Ethanol, Wasser oder in einem Gemisch dieser Lösungsmittel vorgenommen, bei Temperaturen zwischen 0° und 100°C. Weiter ist es von Vorteil, Basen wie Natriumhydroxid zuzusetzen, wie in der Literatur beschrieben (Synthesis 1979, 281; J. Am. Chem. Soc. 102, 1064 (1980); Ann. 1978, 1963).The compounds III are then mixed with the alkylating agent Z- R 4 alkylated. The quaternary pyridinium salts formed in this way are advantageously reduced with lithium aluminum hydride, sodium cyanoborohydride or sodium borohydride in a solvent such as ether, tetrahydrofuran, ethanol, water or in a mixture of these solvents, at temperatures between 0 ° and 100 ° C. It is also advantageous to add bases such as sodium hydroxide, as described in the literature (Synthesis 1979, 281; J. Am. Chem. Soc. 102, 1064 (1980); Ann. 1978, 1963).
Zur Herstellung derjenigen Verbindungen der Formel I, in denen m, n, R2, R 3 die zur Formel I genannte Bedeutung haben, die Reste R zusammen eine Bindung darstellen und R4 ein Wasserstoffatom bedeutet, wird eine Verbindung der allgemeinen Formel V mit Chlorameisensäurephenylester in das Urethan VI
Diese Reaktion erfolgt analog J. Org. Chem. 26, 4057, (1961) und J. Med. Chem. 21, 309, (1978).This reaction takes place analogously to J. Org. Chem. 26, 4057, (1961) and J. Med. Chem. 21, 309, (1978).
Bei der Verfahrensweise b) werden die Verbindungen der allgemeinen Formel III katalytisch hydriert, z.B. mit Palladium auf Tierkohle oder mit Platinoxid als Katalysator in äthanolischer Salzsäure bei Raumtemperatur und Normaldruck, bis zur Aufnahme der theoretischen Menge Wasserstoff. Dabei bilden sich als Nebenprodukte wechselnde Mengen der Tetrahydroisochinolinverbindung VII, worin n, m, R2, R3, A und B die zur Formel I genannte Bedeutung haben und wobei die Gruppe N-R4 gleich N-H ist,
Die Ausgangsmaterialien der allgemeinen Formel II werden wie folgt dargesellt aus 3-Cyanopyridin wird mit Benzylmagnesiumchlorid 3-Pyridylbenzylketon erhalten (vgl. J. Am. Chem. Soc. 78, 674-676 (1956)).The starting materials of the general formula II are prepared as follows from 3-cyanopyridine with 3-pyridylbenzyl ketone with benzylmagnesium chloride (cf. J. Am. Chem. Soc. 78, 674-676 (1956)).
Die analoge Reaktion mit 4-Cyanopyridin ergibt das 4-Pyridylbenzylketon.The analogous reaction with 4-cyanopyridine gives the 4-pyridylbenzyl ketone.
Die gleichen Ketone können durch die in J. Med. Chem. 12, (1969), 851-854 beschriebene Kondensation von Phenylessigsäureethylester bzw. von Benzylcyaniden mit Nikotinsäureethylester bzw. Isonikotinsäureethylester erhalten werden.The same ketones can be obtained by the condensation described in J. Med. Chem. 12, (1969), 851-854 of ethyl phenylacetate or of benzyl cyanides with ethyl nicotinate or ethyl isotonicate.
Die so erhaltenen Ketone reagieren mit Hydroxylamin zu den Oximen, die katalytisch reduziert werden zu den Aminen. Die Umsetzung mit den entsprechenden Säurechloriden ergibt die Amide der Formel II.The ketones thus obtained react with hydroxylamine to give the oximes, which are catalytically reduced to give the amines. The reaction with the corresponding acid chlorides gives the amides of the formula II.
Die erfindungsgemäßen Verbindungen der allgemeinen Formel I zeigen Wirkungen auf das Zentralnervensystem. Sie heben insbesondere die durch Tetrabenazin verursachte Ptosis bei Mäusen auf. Des weiteren hemmen diese Verbindungen die Wiederaufnahme von Noradrenalin in Synaptosomen. Aufgrund dieser Eigenschaften können die erfindungsgemäßen Verbindungen als Wirkstoffe in antidepressiv wirkenden Arzneimitteln verwendet werden.The compounds of general formula I according to the invention show effects on the central nervous system. They especially cancel the ptosis caused by tetrabenazine in mice. Furthermore, these compounds inhibit the reuptake of noradrenaline in synaptosomes. On the basis of these properties, the compounds according to the invention can be used as active ingredients in antidepressant drugs.
Zur Beurteilung der Wirkungen der Verbindungen der Erfindung wurden pharmakologische Versuche wie folgt .durchgeführt:
- A. Akute Toxizität der Maus nach intraperitonealer Applikation (ALD50)
- A. Acute mouse toxicity after intraperitoneal application (ALD 50 )
Als Versuchstiere wurden männliche Mäuse (Gassner, NMRI) mit einem Körpergewicht von 20 - 30 g verwendet. Je 6 Tiere wurden in einer Gruppe getestet. Die Verbindungen wurden in 1 %iger Methyl-hydroxy-ethyl-cellulose (MH) suspendiert und den Tieren intraperitoneal (i.p.) in einem Volumen von 10 ml/kg Körpergewicht verabreicht. Die Verbindungen gemäß der Erfindung wurden in Dosen von 3, 10, 30 und 100 mg/kg i.p. gegeben.Male mice (Gassner, NMRI) with a body weight of 20-30 g were used as test animals. 6 animals were tested in a group. The compounds were suspended in 1% methyl-hydroxy-ethyl-cellulose (MH) and administered to the animals intraperitoneally (i.p.) in a volume of 10 ml / kg body weight. The compounds according to the invention were administered in doses of 3, 10, 30 and 100 mg / kg i.p. given.
Die akute letale Dosis (ALD50) wurde graphisch aus der Anzahl der innerhalb von 24 Stunden nach Applikation der Verbindung verstorbenen Tieren ermittelt. Sie ist in der . folgenden Tabelle 1 aufgeführt.The acute lethal dose (ALD 50 ) was determined graphically from the number of animals that died within 24 hours after application of the compound. It is in the. listed in Table 1 below.
B. Verhütung der durch Tetrabenazin induzierten Ptosis bei Mäusen nach intraperitonealer ApplikationB. Prevention of tetrabenazine-induced ptosis in mice after intraperitoneal application
Als Versuchstiere wurden männliche Mäuse (Gassner, NMRI) mit einem Körpergewicht von 20 - 25 g verwendet. Je 5 . Tiere wurden in einer Gruppe getestet. Die Verbindungen wurden in 1 %iger Methyl-hydroxy-ethyl-cellulose suspendiert und den Tieren intraperitoneal (i.p.) in einem Volumen von 10 ml/kg Körpergewicht verabreicht. Die Verbindungen gemäß der Erfindung wurden in Dosen von 5, 10 und 20 mg/kg i.p. getestet. Die Kontrollgruppe erhielt lediglich 10 ml/kg MH i.p. ohne Wirkstoff.Male mice (Gassner, NMRI) with a body weight of 20-25 g were used as test animals. 5 each Animals were tested in a group. The compounds were suspended in 1% methyl-hydroxy-ethyl-cellulose and administered to the animals intraperitoneally (i.p.) in a volume of 10 ml / kg body weight. The compounds according to the invention were administered in doses of 5, 10 and 20 mg / kg i.p. tested. The control group received only 10 ml / kg MH i.p. without active ingredient.
Die Verbindungen wurden den Tieren 30 Minuten vor der Tetrabenazin-Gabe (TBZ) i.p. verabreicht. Die Kontrollgruppe erhielt lediglich 1 %iger MH und TBZ nach dem gleichen Zeitplan wie die mit den Testsubstanzen behandelten Tiere.The compounds were administered to the animals i.p. 30 minutes prior to tetrabenazine (TBZ) administration. administered. The control group received only 1% MH and TBZ on the same schedule as the animals treated with the test substances.
30 Minuten nach der TBZ-Injektion (TBZ: 40 mg/kg i.p.) wurden die Tiere einzeln in Plastikkästen gesetzt und 1 Minute später nach folgendem Schema die Ptosis festgestellt:The animals were placed individually in plastic boxes 30 minutes after the TBZ injection (TBZ: 40 mg / kg i.p.) and the ptosis was determined 1 minute later according to the following scheme:
Ptosis Index:
Als ED50 wird die Dosis definiert, die den durchschnittlichen Ptosis-Index (maximal 4) um 50 % reduziert.The ED 50 defines the dose that reduces the average ptosis index (maximum 4) by 50%.
Die Ergebnisse sind in der folgenden Tabelle 1 zusammengefaßt.The results are summarized in Table 1 below.
C. Wiederaufnahmehemmung von Noradrenalin in SynaptosomenC. Inhibition of noradrenaline reuptake in synaptosomes
Synaptosomen aus Rattenhirn werden nach der Methode von Whittaker (Handbook of Neurochemistry 2, 327-364, Editor A. Lajtha; London and New York, 1969) isoliert und die Monoamin-Aufnahme nach der Methode von Schacht und Heptner gemessen (Biochemical Pharmac. 23, 3413-3422). Die 14C-Noradrenalin-Aufnahme wurde in einem Krebs-Henseleit-Bikarbonatpuffer pH 7,4 der 11 Millimol Glucose enthielt, gemessen. 2,5 ml der Synaptosomen-Suspension wurden mit markiertem Noradrenalin bei 37°C inkubiert in Gegenwart oder ohne Testsubstanz. Die Inkubationszeit betrug 4 Minuten. Die weitere Aufnahme wurde dann durch Abkühlen mit Eis gestoppt. Um nicht-spezifische Adsorptionen auszuschließen, wurden Kontrollproben bei 0°C unter sonst gleichen Bedingungen inkubiert:
- Die aufgenommenen Noradrenalinmengen wurden mit Hilfe der Membranfiltrationstechnik mit einem Millipore Sampling Manifold mit Cellulosenitratfiltern von 25 mm Durchmesser und 0,6 Mikrometer Porengröße gemessen. Die Synaptosomen wurden unter vermindertem Druck gesammelt und die Radioaktivität in einem Packard-Tricarb-Scintillationszähler bestimmt. Die Menge an angesammelten Noradrenalin wurde angegeben als Prozent Radioaktivität, die zur Inkubationsmischung zugesetzt wurde.
- The amounts of noradrenaline taken up were measured using membrane filtration technology with a Millipore Sampling Manifold with cellulose nitrate filters of 25 mm diameter and 0.6 micron pore size. The synaptosomes were collected under reduced pressure and the radioactivity was determined in a Packard-Tricarb scintillation counter. The amount of noradrenaline accumulated was reported as percent radioactivity added to the incubation mixture.
Die IC50-Werte (inhibition concentration) der nachstehenden Tabelle 1 geben die Konzentration der Testsubstanzen an, welche die Aufnahme von 14 C-Noradrenalin zu 50 % hemmen.The IC 50 (inhibition concentration) values in Table 1 below indicate the concentration of the test substances which inhibit the absorption of 14 C-noradrenaline by 50%.
Die in den Versuchen erhaltenen Werte für die Toxizität der Tetrabenazin-Ptosis und die Wiederaufnahmehemmung einiger Verbindungen gemäß der Erfindung sind in der nachstehenden Tabelle 1 zusammengefaßt.
Die erfindungsgemäßen Verbindungen der allgemeinen Formel I und ihre Salze mit pharmakologisch verträglichen Säuren sind als Antidepressiva innerhalb eines breiten Dosierungsbereiches wirksam. Die Höhe der verabreichten Dosis ist selbstverständlich abhängig von der Art der gewünschten Behandlung, von der Anwendungsweise und von dem Zustand, vom Typ und von der Größe des zu behandelnden Säugetiers. Bei oraler Verabreichung werden befriedigende Ergebnisse mit Dosen von 0,1 - 50 mg an aktiver Substanz pro kg Tierkorpergewicht erzielt, beim Menschen variiert die tägliche Dosis zwischen 10 - 400 mg an aktiver Substanz pro Mensch, vorzugsweise zwishcen 20 - 200 mg, wobei Einzeldosen von 10 - 100 mg, vorzugsweise ein bis dreimal täglich gegeben werden können. Für intravenöse oder intramuskuläre Anwendung beträgt die Dosis 2 - 150 mg, vorzugsweise 5 - 100 mg täglich.The compounds of the general formula I according to the invention and their salts with pharmacologically acceptable acids are active as antidepressants within a wide dosage range. The amount of the administered dose is of course dependent on the type of treatment desired, from the A nwendungsweise and from the state, the type and the size of the mammal to be treated. When administered orally, satisfactory results at doses of 0.1 to - 50 mg of active substance per kg Tierkorpergewicht attained in humans, the daily dose varies between 10 - 400 mg of active substance p ro human, preferably zwishcen 20-200 mg, with single doses from 10 to 100 mg, preferably one to three times a day. For intravenous or intramuscular use, the dose is 2 - 150 mg, preferably 5-100 mg daily.
Die Verbindungen können allein oder mit pharmazeutisch üblichen Hilfsstofen und/oder Trägerstoffen gemischt angewandt werden. Für eine orale Anwendungsform werden die Verbindungen durch übliche Methoden in geeignete Darreichungsformen gebracht, wie Tabletten, Steckkapseln, wäßrige, alkoholische oder ölige Lösungen. Als inerte Träger können z.B. Magnesiumcarbonat, Milchzucker oder Maisstärke verwendet werden. Als ölige Trägerstoffe bzw. Lösungsmittel kommen beispielsweise besonders pflanzliche Öle in Betracht wie Olivenöl oder Sonnenblumenöl.The compounds can be used alone or mixed with conventional pharmaceutical auxiliary substances and / or carriers. For an oral use form, the compounds are brought into suitable dosage forms by conventional methods, such as tablets, push-fit capsules, aqueous, alcoholic or oily solutions. As inert carriers e.g. Magnesium carbonate, milk sugar or corn starch can be used. Vegetable oils such as olive oil or sunflower oil are particularly suitable as oily carriers or solvents.
Die Salze der Verbindungen gemäß der Erfindung werden z.B. mit folgenden Säuren gebildet:
- Chlor-, Brom, oder Jodwasserstoffsäure, Phosphorsäure, Schwefelsäure, Methylschwefelsäure, Amidosulfonsäure, Salpetersäure, Ameisensäure, Essigsäure, Propionsäure, Bernsteinsäure, Weinsäure, Milchsäure, Malonsäure, Fumarsäure, Oxalsäure, Zitronensäure, Äpfelsäure, Schleimsäure, Benzoesäure, Salicylsäure, Acetylaminoessigsäure, 4,4'-Methylen-bis-(3-hydroxy-2-naphtholsäure) (Embonsäure), Naphthalin-1,5-disulfonsäure, Ascorbinsäure, Phenylessigsäure, p-Amino-salicylsäure, Hydroxyethansulfonsäure, Benzolsulfonsäure oder synthetische Harze, die saure Gruppen enthalten, z.B. solche mit Ionenaustauschwirkung. Als Lösungsmittel solcher Salze kommen z. B. in Frage Wasser, physiologische Kochsalzlösungen oder Alkohol, wie z.B. Ethanol, Propandiol oder Glycerin,, daneben auch Zuckerlösungen wie z.B. Glukose- oder Mannitlösungen, oder auch eine Mischung aus den genannten Lösungsmitteln. Solche Lösungen eignen sich auch zur intravenösen Applikation.
- Chloric acid, bromine or hydroiodic acid, phosphoric acid, sulfuric acid, methylsulfuric acid, amidosulfonic acid, nitric acid, formic acid, acetic acid, propionic acid, succinic acid, tartaric acid, lactic acid, malonic acid, fumaric acid, oxalic acid, citric acid, malic acid, mucic acid, benzoic acid, acetic acid, salicamino 4 4'-methylene-bis- (3-hydroxy-2-naphtholic acid) (embonic acid), naphthalene-1,5-disulfonic acid, ascorbic acid, phenylacetic acid, p-amino-salicylic acid, hydroxyethanesulfonic acid, benzenesulfonic acid or synthetic resins containing acidic groups, eg those with an ion exchange effect. As a solvent of such salts such. B. in question water, physiological saline or alcohol, such as ethanol, propanediol or glycerin, in addition also sugar solutions such as glucose or mannitol solutions, or a mixture of the solvents mentioned. Such solutions are also suitable for intravenous application.
4,45 g 6,7-Dimethoxy-1-phenyl-3-(pyrid-3-yl)-isochinolin in 400 ml Aceton gelöst werden mit 2,8 g Methyljodid versetzt und 2 Tage bei Raumtemperatur gerührt. Der Niederschlag wird abfiltriert und ergibt 3,5 g der Pyridiniumverbindung, die in 300 ml Methanol und 580 mg Natriumhydroxid in 50 ml Wasser gelöst wird und bei 0°C werden 1,1 g Natriumborhydrid in 2 Portionen zugegeben. Das Gemisch steht über Nacht bei Raumtemperatur, das Methanol wird im Vakuum abdestilliert und der Rückstand zwischen Toluol und Wasser verteilt. Aus der trockenen Toluolphase werden 2,5 g rötliches öl isoliert. Die Chromatographie an Silicagel mit Chloroform-Methanol (95 : 5)-Gemisch ergibt 2.1 g leicht gelbliches Harz, daß durch ethanolische Salzsäure in 1,75 g kristallines Hydrochlorid mit Schmp. 203 - 207°C übergeht.4.45 g of 6,7-dimethoxy-1-phenyl-3- (pyrid-3-yl) isoquinoline in 400 ml of acetone are mixed with 2.8 g of methyl iodide and stirred for 2 days at room temperature. The precipitate is filtered off and gives 3.5 g of the pyridinium compound, which is dissolved in 300 ml of methanol and 580 mg of sodium hydroxide in 50 ml of water, and at 0 ° C. 1.1 g of sodium borohydride are added in two portions. The mixture stands overnight at room temperature, the methanol is distilled off in vacuo and the residue is partitioned between toluene and water. 2.5 g of reddish oil are isolated from the dry toluene phase. Chromatography on silica gel with a chloroform-methanol (95: 5) mixture gives 2.1 g of a slightly yellowish resin which is converted into 1.75 g of crystalline hydrochloride with a melting point of 203-207 ° C. by means of ethanolic hydrochloric acid.
Das Ausgangsmaterial wird wie folgt dargestellt.The starting material is shown as follows.
5,0 g 3,4-Dihydro-6,7-dimethoxy-1-phenyl-3(pyrid-3-yl) isochinolin werden in 150 ml Diethylenglykoldiethylether unter einer Stickstoffatmosphäre mit 2,5 g Palladium auf Tierkohle (10 %) auf 160°C für 2,5 Stunden erhitzt. Der Katalysator wird abfiltriert, die Lösung einrotiert und der Rückstand mit Ether gewaschen. Es werden 4,0 g der Isochinolinverbindung mit Schmp. 176 - 177°C isoliert.5.0 g of 3,4-dihydro-6,7-dimethoxy-1-phenyl-3 (pyrid-3-yl) isoquinoline are dissolved in 150 ml of diethylene glycol diethyl ether under a nitrogen atmosphere with 2.5 g of palladium on charcoal (10%) Heated 160 ° C for 2.5 hours. The catalyst is filtered off, the solution is spun in, and the residue is washed with ether. 4.0 g of the isoquinoline compound with mp. 176-177 ° C. are isolated.
3.4-Dihydro-6,7-dimethoxy-1-phenyl-3-(pyrid-3yl)isochinolin3,4-dihydro-6,7-dimethoxy-1-phenyl-3- (pyrid-3yl) isoquinoline
1,8 g N-[2-(3,4-Dimethoxyphenyl)-1-(3-pyridyl)ethyl] benzoesäureamid werden in 20 ml Phosphoroxichlorid 5 Stunden bei 60°C und 1,5 Stunden bei 120°C gerührt. Der gelbe Niederschlag wird abgesaugt, in 200 ml Wasser gelöst, die Lösung mit Kaliumcarbonat alkalisch gestellt und zweimal mit Methylenchlorid extrahiert. Es werden 1.6 g Dihydroisochinolinverbindung mit Schmp. 180 - 182°C isoliert.1.8 g of N- [2- (3,4-dimethoxyphenyl) -1- (3-pyridyl) ethyl] benzoic acid amide are stirred in 20 ml of phosphorus oxychloride for 5 hours at 60 ° C. and 1.5 hours at 120 ° C. The yellow precipitate is filtered off, dissolved in 200 ml of water, the solution made alkaline with potassium carbonate and extracted twice with methylene chloride. 1.6 g of dihydroisoquinoline compound with a melting point of 180 ° -182 ° C. are isolated.
N-[2-(3.4-Dimethoxyphenyl)-1-(3-pyridyl)ethyl]benzoesäureamidN- [2- (3,4-Dimethoxyphenyl) -1- (3-pyridyl) ethyl] benzoic acid amide
14,9 g 2-(3.4-Dimethoxyphenyl)-1-(3-pyridyl)ethylamin und 12.1 g Triethylamin in 200 ml Chloroform werden unter Eiskühlung und 9.75 g Benzoylchlorid in 10 ml Chloroform versetzt. Es wird 4 Stunden bei Raumtemperatur nachgerührt, im Vakuum das Chloroform abdestilliert und der Rückstand mit Toluol und Wasser gewaschen. 18,5 g des Amids mit Schmp. 156 - 158°C werden erhalten.14.9 g of 2- (3.4-dimethoxyphenyl) -1- (3-pyridyl) ethylamine and 12.1 g of triethylamine in 200 ml of chloroform are added while cooling with ice and 9.75 g of benzoyl chloride in 10 ml of chloroform. The mixture is stirred for 4 hours at room temperature, the chloroform is distilled off in vacuo and the residue is washed with toluene and water. 18.5 g of the amide with mp. 156-158 ° C. are obtained.
2-(3.4--Dimethoxyphenyl)-1-(3-pyridyl)ethylamin2- (3.4 - dimethoxyphenyl) -1- (3-pyridyl) ethylamine
23,1 g 3,4-Dimethoxybenzyl-3-pyridyl-keton werden in 150 ml Pyridin mit 12,5 g Hydroxylamin-Hydrochlorid in das Oxim überführt. Es werden 16,8 g Oxim mit Schmp. 119 - 121°C isoliert. Das Oxim wird in 400 ml Isopropanol und 200 ml methanolischen Ammoniak gelöst und bei Raumtemperatur mit Raney-Nickel hydriert. Nach Aufnahme der theoretischen Menge Wasserstoff wird der Katalysator abfiltriert und die Lösung einrotiert. Das ölige Amin wird ohne weitere Reinigung in das Amid überführt.23.1 g of 3,4-dimethoxybenzyl-3-pyridyl-ketone are converted into the oxime in 150 ml of pyridine with 12.5 g of hydroxylamine hydrochloride. 16.8 g of oxime with mp 119 ° -121 ° C. are isolated. The oxime is dissolved in 400 ml of isopropanol and 200 ml of methanolic ammonia and hydrogenated with Raney nickel at room temperature. After the theoretical amount of hydrogen has been taken up, the catalyst is filtered off and the solution is spun in. The oily amine is converted into the amide without further purification.
3.4-Dimethoxybenzyl-3-pyridylketon3,4-dimethoxybenzyl - 3-pyridyl ketone
Zu einer siedenden Natriumethylatlösung, dargestellt aus 6 g Natrium und 100 ml Ethanol, wird das Gemisch von 45,4 g Nicotinsäureethylester und 35,4 g 3.4-Dimethoxybenzylcyanid getropft. Die Mischung wird 5 Stunden am Rückfluß gehalten und nach dem Abkühlen in 1 1 Wasser eingegossen. Der überschüssige Nicotinsäureester wird mit Toluol entfernt und die wässrige Lösung mit Eisessig neutralisiert, wobei 50,7 g α-Cyano-3,4-dimethoxybenzyl-3-pyridylketon kristallin ausfallen (Schmp. 149 - 152°C). Dieses Cyanoketon (31,0 g) wird in 6 n Salzsäure bei 80 - 90°C hydrolisiert. Das Hydrochlorid des 3,4-Dimethoxybenzyl-3-pyridylketcn kristallisiert aus Ethanol mit Schmp. 188 - 1910C und die freie Base zeigt einen Schmp. von 60 - 64°C. Die Verbindung wird ohne weiter Reinigung zum Oxim umgesetzt.The mixture of 45.4 g of ethyl nicotinate and 35.4 g of 3,4-dimethoxybenzyl cyanide is added dropwise to a boiling sodium ethylate solution, prepared from 6 g of sodium and 100 ml of ethanol. The mixture is refluxed for 5 hours and, after cooling, poured into 1 liter of water. The excess nicotinic acid ester is removed with toluene and the aqueous solution is neutralized with glacial acetic acid, 50.7 g of α-cyano-3,4-dimethoxybenzyl-3-pyridyl ketone precipitating in crystalline form (mp. 149-152 ° C.). This cyanoketone (31.0 g) is hydrolyzed in 6N hydrochloric acid at 80-90 ° C. The hydrochloride of 3,4-Dimethoxy-3-pyridylketcn crystallized from ethanol with mp 188 -. 191 0 C and the free base shows a melting point of 60 -. 64 ° C. The compound is converted to the oxime without further purification.
3-(1-Ethyl-1,2,5,6-tetrahydropyrid-4-yl)-1-(2-methylphenyl)isochinolin3- (1-ethyl-1,2,5,6-tetrahydropyrid-4-yl) -1- (2-methylphenyl) isoquinoline
4,5 g 1-(2-Methylphenyl)-3-(pyrid-4-yl)isochinolin werden mit 2,5 g Ethyljodid in 50 ml Ethanol in das N-Ethylpyridiniumjodid überführt. Nach 7 Stunden Kochen wird das Ethanol abdestilliert und der Rückstand in 200 ml Methanol und 25 ml Wasser gelöst. Bei Raumtemperatur werden 1,2 g Natriumhydroxid in 25 ml Wasser und dann 1,7 g Natriumborhydrid in 2-Portionen zugegeben. Nach 6 Stunden bei Raumtemperatur wird wie in Beispiel 1 aufgearbeitet und chromatographiert. Die Base (2,8 g) wird als helles öl isoliert und mit ethanolischer Salzsäure in das Hydrochlorid (1,6 g) mit Schmp. 176 - 179°C überführt.4.5 g of 1- (2-methylphenyl) -3- (pyrid-4-yl) isoquinoline are converted into the N-ethylpyridinium iodide with 2.5 g of ethyl iodide in 50 ml of ethanol. After 7 hours of boiling, the ethanol is distilled off and the residue is dissolved in 200 ml of methanol and 25 ml of water. At room temperature, 1.2 g of sodium hydroxide in 25 ml of water and then 1.7 g of sodium borohydride are added in two portions. After 6 hours at room temperature, the mixture is worked up and chromatographed as in Example 1. The base (2.8 g) is isolated as a light oil and with ethanolic hydrochloric acid in the hydrochloride (1.6 g) with mp. 176 - 179 ° C. transferred.
Das Ausgangsmaterial wird wie folgt dargestellt.The starting material is shown as follows.
1-(2-Methylphenyl)-3-(pyrid-4-yl)isochinolin1- (2-methylphenyl) -3- (pyrid-4-yl) isoquinoline
37 g N-[2-Phenyl-1-(4-pyridyl)ethyl]-2-methylbenzoe- säureamid in 800 ml Tetralin mit 240 g Phosphorpentoxid und 60 g Celite-Filterhilfsmittel zur besseren Verteilung 5 Stunden auf 180 - 200°C erhitzt. Nach dem Abkühlen auf 120 - 140°C werden weitere 120 g Phosphorpentoxid zugegeben und 16 Stunden auf 230°C (Rückfluß) erhitzt. Nach dem Abkühlen wird das Tetralin abdekantiert und mit Toluol mehrmals gewaschen. Der gewaschene Rückstand wird in Toluol suspendiert und unter Rühren langsam mit Wasser versetzt. Die wässrige Phase wird abgetrennt und mit Kaliumhydroxid stark alkalisch gemacht. Das Produkt wird mit Toluol extrahiert und nach dem Abdestillieren des Toluols an Silicagel mit Chloroform Essigsäureethylester (8 : 2) chromatographiert. Es werden 25 g ölige Base isoliert, die mit ethanolischer Salzsäure ein Hydrochlorid mit Schmp. 255 - 259°C vergibt.37 g of N- [2-phenyl-1- (4-pyridyl) ethyl] -2-methylbenzoic acid amide in 800 ml of tetralin with 240 g of phosphorus pentoxide and 60 g of Celite filter aid were heated at 180-200 ° C. for 5 hours for better distribution . After cooling to 120-140 ° C., a further 120 g of phosphorus pentoxide are added and the mixture is heated to 230 ° C. (reflux) for 16 hours. After cooling, the tetralin is decanted off and washed several times with toluene. The washed residue is suspended in toluene and water is slowly added while stirring. The aqueous phase is separated off and made strongly alkaline with potassium hydroxide. The product is extracted with toluene and, after the toluene has been distilled off, chromatographed on silica gel with chloroform-ethyl acetate (8: 2). 25 g of an oily base are isolated which, using ethanolic hydrochloric acid, assigns a hydrochloride with a melting point of 255-259 ° C.
N-[2-Phenyl-1-(4-pyridyl)ethyl]-2-methylbenzoesäureamidN- [2-phenyl-1- (4-pyridyl) ethyl] -2-methylbenzoic acid amide
56,0 g 2-Phenyl-1-(4-pyridyl)ethylamin und 60 g Triethylamin werden in 800 ml Chloroform unter Eiskühlung mit 48,0 g 2-Methylbenzoylchlorid versetzt. Die Mischung wird 2 Stunden bei Raumtemperatur nachgerührt und dann mit Natriumhydrogencarbonatlösung und Wasser gewaschen. Nach dem Trocknen der Chloroformlösung wird das Lösungsmittel abdestilliert und der ölige Rückstand mit Äther kristallisiert. Es werden 48 g Amid mit Schmp. 168 - 170°C isoliert.56.0 g of 2-phenyl-1- (4-pyridyl) ethylamine and 60 g of triethylamine in 800 ml of chloroform are treated with 48.0 g of 2-methylbenzoyl chloride while cooling with ice. The mixture is stirred for 2 hours at room temperature and then washed with sodium hydrogen carbonate solution and water. After the chloroform solution has dried, the solvent is distilled off and the oily residue is crystallized with ether. 48 g of amide with mp. 168-170 ° C. are isolated.
5,34 g Benzyl-4-pyridyl-keton und 3,75 g Hydroxylamin-hydrochlorid werden in 50 ml Pyridin 4 Stunden zum Sieden erhitzt. Nach dem Abkühlen wird in 600 ml Wasser eingerührt und das Oxim (5,6 g) mit Schmp. 194 - 1960C abfiltriert. Das Oxim wird in Isopropanol mit Raney-Nickel bei 50°C und Normaldruck mit Wasserstoff hydriert. Nach der üblichen Aufarbeitung erhält man das Amin als hellgelbes öl.5.34 g of benzyl-4-pyridyl ketone and 3.75 g of hydroxylamine hydrochloride are boiled in 50 ml of pyridine for 4 hours. After cooling, it is stirred into 600 ml water and the oxime (5.6 g), m.p. 194 -. 196 0 C filtered off. The oxime is hydrogenated in isopropanol with Raney nickel at 50 ° C. and normal pressure with hydrogen. After the usual work-up, the amine is obtained as a light yellow oil.
Aus 6.6 g Magnesiumspäne und 34,2 g Benzylchlorid wird nach bekannten Methoden die Benzylmagnesiumchlorid-Verbindung in Ether hergestellt. Unter Eiskühlung werden 26 g 4-Cyanopyridin in 200 ml Ether zur Grignard-Verbindung getropft, wobei ein dicker Kristallbrei entsteht, der 20 Stunden bei Raumtemperatur nachgerührt wird.The benzyl magnesium chloride compound in ether is prepared from 6.6 g of magnesium shavings and 34.2 g of benzyl chloride by known methods. While cooling with ice, 26 g of 4-cyanopyridine in 200 ml of ether are added dropwise to the Grignard compound, a thick crystal slurry being formed which is stirred at room temperature for 20 hours.
Die Reaktionsmischung wird langsam mit 50 ml Wasser und 100 ml 5 n Salzsäure hydrolysiert. Die wässrige Phase 1,5 Stunden auf dem Dampfbad erhitzt, mit Kaliumcarbonat alkalisch gestellt und mit Toluol extrahiert. Aus der Toluolphase wird nach Kristallisation aus Äther 5.6 g des Ketons mit Schmp. 94 - 96° isoliert.The reaction mixture is slowly hydrolyzed with 50 ml of water and 100 ml of 5N hydrochloric acid. The aqueous phase was heated for 1.5 hours on a steam bath, made alkaline with potassium carbonate and extracted with toluene. After crystallization from ether, 5.6 g of the ketone with a melting point of 94-96 ° is isolated from the toluene phase.
Zu 7.7 g 3-(1-Benzyl-1,2,5,6-tetrahydropyrid-4-yl)-1-(2-methylphenyl)isochinolin und 8.1 g Triethyl- - amin in 150 ml Chloroform werden bei 0°C 12,5 g Chlorameisensäurephenylester getropft. Die Reaktionsmischung wird 15 Stunden bei Raumtemperatur gerührt. Nach dem Abdestillieren des Lösungsmittels wird der Rückstand zwischen Toluol und 0,2 n Natronlauge verteilt. Die Toluolphase wird eingeengt und der Rückstand in 200 ml Äthanol mit 200 ml 10 % Natronlauge 17.Stunden bei 60°C hydrolysiert. Das Lösungsmittel wird wieder abdestilliert und der Rückstand in Toluol mit Wasser gewaschen. Man isoliert 4,5 g der amorphen Base, die mit ethanolischer Salzsäure 1,9 g des Hydrochlorids mit Schmp. 276 - 278°C ergibt.7.7 g of 3- (1-benzyl-1,2,5,6-tetrahydropyrid-4-yl) -1- (2-methylphenyl) isoquinoline and 8.1 g of triethyl amine in 150 ml of chloroform are 12 at 0 ° C , 5 g of phenyl chloroformate were added dropwise. The reaction mixture is stirred for 15 hours at room temperature. After the solvent has been distilled off, the residue is partitioned between toluene and 0.2N sodium hydroxide solution. The toluene phase is concentrated and the residue is hydrolyzed in 200 ml of ethanol with 200 ml of 10% sodium hydroxide solution at 60 ° C. for 17 hours. The solvent is distilled off again and the residue is washed with water in toluene. 4.5 g of the amorphous base are isolated, which, with ethanolic hydrochloric acid, gives 1.9 g of the hydrochloride having a melting point of 276-278 ° C.
Analog zu den-voranbeschriebenen Beispielen lassen sich die Verbindungen der Tabelle 2 und 3 darstellen.
7.7 g 1-Phenyl-3-(pyrid-4-yl)-isochinolin werden mit 0,5 g Platinoxid in 800 ml Ethanol bei Raumtemperatur und Normaldruck 24 Stunden hydriert. Der Katalysator wird abfiltriert, die Lösung einrotiert und der Rückstand zwischen Chloroform und Wasser verteilt. Die Chloroformlösung wird eingedampft und der Rückstand in Äther gelöst. Es kristallisieren 1,95 g 1-Phenyl-3-.(piperidin-4-yl)-1,2,3,4-tetrahydroisochinolin mit Schmp. 141 - 142° aus.7.7 g of 1-phenyl-3- (pyrid-4-yl) isoquinoline are hydrogenated with 0.5 g of platinum oxide in 800 ml of ethanol at room temperature and normal pressure for 24 hours. The catalyst is filtered off, the solution is spun in, and the residue is partitioned between chloroform and water. The chloroform solution is evaporated and the residue is dissolved in ether. 1.95 g of 1-phenyl-3 -. (Piperidin-4-yl) -1,2,3,4-tetrahydroisoquinoline with mp 141-142 ° crystallize out.
Die Mutterlauge enthält 5,6 g eines Substanzgemisches, das durch Chromatographie getrennt wird. Man isoliert 2,8 g 1-Phenyl-3-(piperidin-4-yl)isochinolin, das als Hydrochlorid bei 238 - 242°C schmilzt.The mother liquor contains 5.6 g of a mixture of substances, which is separated by chromatography. 2.8 g of 1-phenyl-3- (piperidin-4-yl) isoquinoline are isolated, which melts at 238-242 ° C. as the hydrochloride.
1-(2-Methylphenyl)-3-(piperidin-4-yl)-isochinolin-Hydrochlorid mit Schmelzpunkt 235 - 236°C wird in analoger Verfahrensweise wie in Beispiel 21 beschrieben aus 1-(2-Methylphenyl)-3-(pyrid.-4-yl)-isochinolin erhalten.1- (2-methylphenyl) -3- (piperidin-4-yl) isoquinoline hydrochloride with melting point 235-236 ° C. is obtained from 1- (2-methylphenyl) -3- (pyride) in an analogous procedure as described in Example 21 .-4-yl) -isoquinoline obtained.
Aus 1,3 g 1-(2-Methylphenyl)-3-(piperidin-4-yl)isochinolin Hydrochlorid wird mit Kaliumcarbonat die Base freigesetzt und in 40 ml Toluol gelöst. Diese Lösung wird mit 0,82 g Natriumcarbonat, 0,1 g Kaliumjodid und 0,61 g Allylbromid 15 Stunden bei Raumtemperatur und dann noch 2 Stunden bei 50°C gerührt. Die Reaktionsmischung wird zwischen Toluol und Wasser verteilt und aus der Toluollösung werden 1.2 g eines hellen Öls isoliert, das in Isopropanol mit Oxalsäure in 1,4 g des Oxalats mit Schmelzpunkt 217 - 219°C überführt werden kann.The base is released from 1.3 g of 1- (2-methylphenyl) -3- (piperidin-4-yl) isoquinoline hydrochloride with potassium carbonate and dissolved in 40 ml of toluene. This solution is stirred with 0.82 g sodium carbonate, 0.1 g potassium iodide and 0.61 g allyl bromide for 15 hours at room temperature and then for a further 2 hours at 50 ° C. The reaction mixture is partitioned between toluene and water and 1.2 g of a light oil are isolated from the toluene solution, which can be converted into 1.4 g of the oxalate with melting point 217-219 ° C. in isopropanol with oxalic acid.
Analog zu den voran beschriebenen Beispielen 21 - 23 werden die Verbindungen der Tabelle 4 dargestellt
Claims (4)
und gegebenenfalls eine so erhaltene'Verbindung der allgemeinen Formel I mit einem Alkylierungsmittel der allgemeinen Formel Z-R4 umsetzt, zu einer Verbindung der allgemeinen Formel I, worin m, n, R 2, R 3, A und B die zur Formel I genannten Bedeutungen haben und die Reste R Wasserstoff und R4 Benzyl oder einen geradkettigen oder verzweigten, gesättigten oder ungesättigten C1-C6-Alkylrest bedeuten.
and optionally reacting a compound of the general formula I thus obtained with an alkylating agent of the general formula ZR 4 to give a compound of the general formula I in which m, n, R 2 , R 3 , A and B have the meanings given for the formula I. and the radicals R are hydrogen and R 4 is benzyl or a straight-chain or branched, saturated or unsaturated C 1 -C 6 -alkyl radical.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT83111922T ATE22077T1 (en) | 1982-12-02 | 1983-11-29 | 1-PHENYLISOCHINOLINE DERIVATIVES AND PROCESS FOR THEIR MANUFACTURE, PHARMACEUTICAL PREPARATIONS CONTAINING THIS COMPOUND AND THEIR USE. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19823244594 DE3244594A1 (en) | 1982-12-02 | 1982-12-02 | 1-PHENYLISOCHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THIS COMPOUND AND THE USE THEREOF |
DE3244594 | 1982-12-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0110372A1 true EP0110372A1 (en) | 1984-06-13 |
EP0110372B1 EP0110372B1 (en) | 1986-09-10 |
Family
ID=6179625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP83111922A Expired EP0110372B1 (en) | 1982-12-02 | 1983-11-29 | 1-phenylisoquinoline derivatives, process for their preparation, pharmaceutical compositions containing these compounds and their use |
Country Status (5)
Country | Link |
---|---|
US (1) | US4547508A (en) |
EP (1) | EP0110372B1 (en) |
JP (1) | JPS59110691A (en) |
AT (1) | ATE22077T1 (en) |
DE (2) | DE3244594A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009007457A2 (en) * | 2007-07-12 | 2009-01-15 | Exonhit Therapeutics Sa | Compounds and methods for modulating rho gtpases |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8800397D0 (en) * | 1988-01-08 | 1988-02-10 | Sandoz Ltd | Improvements in/relating to organic compounds |
GB9322828D0 (en) * | 1993-11-05 | 1993-12-22 | Sandoz Ltd | Organic compounds |
CN101817784B (en) * | 1996-04-25 | 2012-02-01 | 日产化学工业株式会社 | Ethylene derivatives and pesticides containing said derivatives |
AU6946998A (en) * | 1997-04-24 | 1998-11-13 | American Home Products Corporation | Process for the synthesis of 4-{6-(hexylcarbamoyloxy) hexylcarbamoyloxy}-piperidine-1- carboxylic acid 4-phenoxyphenyl ester |
CN101891682B (en) | 2003-03-28 | 2012-07-04 | 日产化学工业株式会社 | Process for producing acrylonitrile compound |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
KR101897881B1 (en) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | Certain chemical entities, compositions and methods |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
JP5789252B2 (en) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | Heterocyclic compounds and uses thereof |
EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
WO2012064973A2 (en) * | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
CN103930422A (en) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
JP6027611B2 (en) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Heterocyclic compounds and uses thereof |
AU2012302197B2 (en) | 2011-08-29 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
JP6466924B2 (en) | 2013-10-04 | 2019-02-06 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Heterocyclic compounds and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
DK3119397T3 (en) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of PI3K-gamma-mediated disorders |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20180058741A (en) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | Solid form of isoquinolines, a process for their preparation, compositions comprising them and methods for using them |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA3028718A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1528738A (en) * | 1976-06-14 | 1978-10-18 | Merck Patent Gmbh | Isoquinolines and their preparation |
EP0047923A1 (en) * | 1980-09-10 | 1982-03-24 | Hoechst Aktiengesellschaft | Isoquinoline derivatives, processes for their preparation and pharmaceutical compositions containing them |
FR2496653A1 (en) * | 1980-12-22 | 1982-06-25 | Delalande Sa | Aminoalkyl di:hydro-naphthalene, isoquinoline and benzoxazepine cpds. - useful as analgesics and antidepressants |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1620496A1 (en) * | 1965-03-24 | 1970-01-02 | Thomae Gmbh Dr K | Process for the preparation of new 1-pyridyl-3,4-dihydroisoquinolines |
DE1620549A1 (en) * | 1966-06-16 | 1970-08-20 | Thomae Gmbh Dr K | Process for the preparation of new pyridyl-tetrahydroisoquinolines |
GB1400425A (en) * | 1971-09-22 | 1975-07-16 | Rolland Sa A | Substituted 3-hydroxymethyl-isoquinolines and derivatives |
DE2210667A1 (en) * | 1972-03-06 | 1973-09-20 | Bayer Ag | 4-naphthyl-1,4-dihydropyridine-dicarboxylates - as coronary dilators from naphthaldehydes, acetoacetates and amines |
SE8107537L (en) * | 1980-12-22 | 1982-06-23 | Delalande Sa | NEW DERIVATIVES OF HETEROCYCLIC AMINOALCOYLES, THEIR PREPARATIONS AND THEIR THERAPEUTIC APPLICATIONS |
-
1982
- 1982-12-02 DE DE19823244594 patent/DE3244594A1/en not_active Withdrawn
-
1983
- 1983-11-29 EP EP83111922A patent/EP0110372B1/en not_active Expired
- 1983-11-29 DE DE8383111922T patent/DE3366141D1/en not_active Expired
- 1983-11-29 AT AT83111922T patent/ATE22077T1/en not_active IP Right Cessation
- 1983-11-30 US US06/556,684 patent/US4547508A/en not_active Expired - Fee Related
- 1983-12-01 JP JP58225528A patent/JPS59110691A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1528738A (en) * | 1976-06-14 | 1978-10-18 | Merck Patent Gmbh | Isoquinolines and their preparation |
EP0047923A1 (en) * | 1980-09-10 | 1982-03-24 | Hoechst Aktiengesellschaft | Isoquinoline derivatives, processes for their preparation and pharmaceutical compositions containing them |
FR2496653A1 (en) * | 1980-12-22 | 1982-06-25 | Delalande Sa | Aminoalkyl di:hydro-naphthalene, isoquinoline and benzoxazepine cpds. - useful as analgesics and antidepressants |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009007457A2 (en) * | 2007-07-12 | 2009-01-15 | Exonhit Therapeutics Sa | Compounds and methods for modulating rho gtpases |
WO2009007457A3 (en) * | 2007-07-12 | 2009-03-26 | Exonhit Therapeutics Sa | Compounds and methods for modulating rho gtpases |
Also Published As
Publication number | Publication date |
---|---|
DE3366141D1 (en) | 1986-10-16 |
DE3244594A1 (en) | 1984-06-07 |
JPS59110691A (en) | 1984-06-26 |
ATE22077T1 (en) | 1986-09-15 |
EP0110372B1 (en) | 1986-09-10 |
US4547508A (en) | 1985-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0110372B1 (en) | 1-phenylisoquinoline derivatives, process for their preparation, pharmaceutical compositions containing these compounds and their use | |
DE2229695A1 (en) | 2- (HETEROARYL-METHYL) -5,9 BETA-DIALKYL6,7-BENZOMORPHANES, THEIR ACID ADDITIONAL SALTS AND THE PROCESS FOR THEIR PRODUCTION | |
DE2847622A1 (en) | NEW CHINAZOLINE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE DERIVATIVES | |
DE2002840A1 (en) | 2,3,5-trisubstitute, -2'-hydroxy-6,7-benzomorphane and process for their preparation | |
EP0047923A1 (en) | Isoquinoline derivatives, processes for their preparation and pharmaceutical compositions containing them | |
DD147537A5 (en) | PROCESS FOR THE PREPARATION OF 1,2,4,5-TETRA-ALKYL-4-ARYL-PIPERIDINES | |
DE2408476C2 (en) | ||
EP0105210B1 (en) | Isoquinoline derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
CH500983A (en) | Aminoisoquinoline derivs spasmolytic depressives | |
DE2841126C2 (en) | ||
EP0064685A1 (en) | Dibenzo(de,g)quinolines, processes for their preparation and pharmaceutical preparations containing them | |
EP0266532A1 (en) | 1,3-Disubstituted imidazolium salts | |
US2820040A (en) | Substituted mono-ammonium salts | |
DE1092476B (en) | Process for the preparation of phenthiazine derivatives | |
DE2034588B2 (en) | ej-Dimethoxy ^ -benzylisoquinolines, process for their preparation and pharmaceuticals | |
AT227701B (en) | Process for the preparation of new octahydroisoquinoline derivatives | |
DE1137025B (en) | Process for the preparation of phenthiazine derivatives | |
DE3604754A1 (en) | Novel isoquinoline derivatives, process for their preparation, pharmaceutical preparations containing these compounds and their use | |
DE1493522C (en) | Process for the preparation of diphenyl propylamine derivatives | |
CH605924A5 (en) | Antidepressant 4-benzofuranyl-piperidine and pyridine derivs. | |
AT219041B (en) | Process for the preparation of new tetrahydroisoquinoline derivatives | |
AT256111B (en) | Process for the preparation of the racemic and the (+) - form of the new 1- (2 ', 4', 5'-trichlorophenethyl) -2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline and their acid addition salts | |
DE1445875C (en) | () 2 Dehydroemetine compounds and a process for their preparation | |
DE3843481A1 (en) | SUBSTITUTED 3-AZABICYCLO / 3.1.1 / HEPTANESE, THEIR PREPARATION AND THEIR USE | |
DE3227741A1 (en) | 1-Phenylisoquinoline derivatives and process for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19841107 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 22077 Country of ref document: AT Date of ref document: 19860915 Kind code of ref document: T |
|
ITF | It: translation for a ep patent filed |
Owner name: ING. C. GREGORJ S.P.A. |
|
REF | Corresponds to: |
Ref document number: 3366141 Country of ref document: DE Date of ref document: 19861016 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19861030 Year of fee payment: 4 |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19861130 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19861130 Year of fee payment: 4 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Effective date: 19871129 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19871130 Ref country code: LI Effective date: 19871130 Ref country code: CH Effective date: 19871130 Ref country code: BE Effective date: 19871130 |
|
BERE | Be: lapsed |
Owner name: HOECHST A.G. Effective date: 19871130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19880601 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19880729 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19880802 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881122 |
|
EUG | Se: european patent has lapsed |
Ref document number: 83111922.7 Effective date: 19880913 |